Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12187440 | 0.88 | ALDH1A1 (0.50) | ALDH1A1TSHRLMNAL3MBTL1NPSR1 | |
| SCHEMBL14146108 | 0.82 | HSD11B1 (0.49) | ALDH1A1LMNAL3MBTL1HTTGAA | |
| SCHEMBL4122614 | 0.82 | TSHR (0.53) | ALDH1A1TSHRLMNAL3MBTL1NPSR1 | |
| SCHEMBL4115804 | 0.82 | PKM (0.60) | ALDH1A1TSHRL3MBTL1NPSR1HTT | |
| SCHEMBL13883807 | 0.81 | ALDH1A1 (0.66) | ALDH1A1TSHRLMNANPSR1HTT | |
| SCHEMBL4117824 | 0.80 | TSHR (0.56) | ALDH1A1TSHRLMNAL3MBTL1NPSR1 | |
| Water SCHEMBL4116761 | 0.79 | TSHR (0.55) | ALDH1A1TSHRLMNAL3MBTL1NPSR1 | |
| SCHEMBL4125131 | 0.79 | NPSR1 (0.56) | ALDH1A1TSHRLMNAL3MBTL1NPSR1 | |
| SCHEMBL4462435 | 0.76 | KMT2A (0.61) | ALDH1A1TSHRLMNAL3MBTL1GAA | |
| SCHEMBL4123848 | 0.74 | CTSS (0.54) | ALDH1A1LMNAHTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1939205-A1 | TRICYCLIC COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | FDFT1, COASY, HMGCR | ALDH1A1 1587/4885TSHR 1672/4885LMNA 1109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.